JBIO
Jade Biosciences, Inc.
Price Chart
No historical data available
Latest Quote
$20.88
+0.04 (+0.19%)
Current Price
| Previous Close | $20.84 |
| Open | $20.65 |
| Day High | $21.09 |
| Day Low | $20.35 |
| Volume | 118,934 |
Stock Information
| Shares Outstanding | 63.60M |
| Total Debt | $1.39M |
| Cash Equivalents | $461.20M |
| Net Income | $-124.44M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.33B |
| EPS (TTM) | $-1.07 |
| Exchange | NCM |
Recent Price History
No history data available. Data will be fetched automatically.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on JBIO.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Revenue | |
| Total Revenue | $0 |
| Operating Revenue | $0 |
| Expenses | |
| Total Expenses | $113,542,000 |
| Other Income Expense | $-21,592,000 |
| Other Non Operating Income Expenses | $-21,592,000 |
| Net Non Operating Interest Income Expense | $7,782,000 |
| Operating Expense | $113,542,000 |
| General And Administrative Expense | $20,421,000 |
| Income & Earnings | |
| Net Income From Continuing Operation Net Minority Interest | $-127,410,000 |
| Net Interest Income | $7,782,000 |
| Interest Income | $7,782,000 |
| Normalized Income | $-127,410,000 |
| Net Income From Continuing And Discontinued Operation | $-127,410,000 |
| Total Operating Income As Reported | $-113,542,000 |
| Net Income Common Stockholders | $-127,410,000 |
| Net Income | $-127,410,000 |
| Net Income Including Noncontrolling Interests | $-127,410,000 |
| Net Income Continuous Operations | $-127,410,000 |
| Pretax Income | $-127,352,000 |
| Interest Income Non Operating | $7,782,000 |
| Operating Income | $-113,542,000 |
| Per Share | |
| Diluted EPS | $-3.19 |
| Basic EPS | $-3.19 |
| Other | |
| Tax Effect Of Unusual Items | $0 |
| Tax Rate For Calcs | $0 |
| Normalized EBITDA (Bullshit earnings) | $-113,516,000 |
| Reconciled Depreciation | $26,000 |
| EBITDA (Bullshit earnings) | $-113,516,000 |
| EBIT | $-113,542,000 |
| Diluted Average Shares | $31,359,958 |
| Basic Average Shares | $31,359,958 |
| Diluted NI Availto Com Stockholders | $-127,410,000 |
| Tax Provision | $58,000 |
| Research And Development | $93,121,000 |
| Selling General And Administration | $20,421,000 |
| Other Gand A | $7,730,000 |
| Salaries And Wages | $12,691,000 |
Fetched: 2026-08-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $332,518,000 | $-46,799,000 |
| Total Assets | $349,781,000 | $72,799,000 |
| Total Non Current Assets | $965,000 | $3,145,000 |
| Other Non Current Assets | $69,000 | $3,145,000 |
| Current Assets | $348,816,000 | $69,654,000 |
| Other Current Assets | $12,658,000 | $268,000 |
| Cash Cash Equivalents And Short Term Investments | $336,158,000 | $69,386,000 |
| Cash And Cash Equivalents | $88,438,000 | $69,386,000 |
| Debt | ||
| Total Debt | $724,000 | $107,600,000 |
| Long Term Debt And Capital Lease Obligation | $724,000 | $107,600,000 |
| Net Debt | - | $38,214,000 |
| Long Term Debt | - | $107,600,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $17,263,000 | $119,598,000 |
| Total Non Current Liabilities Net Minority Interest | $724,000 | $107,602,000 |
| Current Liabilities | $16,539,000 | $11,996,000 |
| Payables And Accrued Expenses | $13,216,000 | $8,128,000 |
| Payables | $2,151,000 | $1,290,000 |
| Accounts Payable | $2,151,000 | $1,290,000 |
| Other Current Liabilities | - | $1,077,000 |
| Equity | ||
| Common Stock Equity | $332,516,000 | $-46,799,000 |
| Preferred Stock Equity | $2,000 | - |
| Total Equity Gross Minority Interest | $332,518,000 | $-46,799,000 |
| Stockholders Equity | $332,518,000 | $-46,799,000 |
| Gains Losses Not Affecting Retained Earnings | $129,000 | $0 |
| Other Equity Adjustments | $129,000 | - |
| Retained Earnings | $-174,389,000 | $-46,979,000 |
| Preferred Securities Outside Stock Equity | $0 | $2,000 |
| Other | ||
| Ordinary Shares Number | $49,316,287 | $32,235,926 |
| Share Issued | $49,316,287 | $32,235,926 |
| Tangible Book Value | $332,516,000 | $-46,799,000 |
| Invested Capital | $332,516,000 | $60,801,000 |
| Working Capital | $332,277,000 | $57,658,000 |
| Capital Lease Obligations | $724,000 | $0 |
| Total Capitalization | $332,518,000 | $60,801,000 |
| Additional Paid In Capital | $506,771,000 | $179,000 |
| Capital Stock | $7,000 | $1,000 |
| Common Stock | $5,000 | $1,000 |
| Preferred Stock | $2,000 | $0 |
| Long Term Capital Lease Obligation | $724,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,323,000 | $2,791,000 |
| Current Accrued Expenses | $11,065,000 | $6,838,000 |
| Net PPE | $896,000 | $0 |
| Gross PPE | $896,000 | $0 |
| Other Properties | $896,000 | - |
| Other Short Term Investments | $247,720,000 | $0 |
Fetched: 2026-08-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-94,885,000 |
| Operating Activities | |
| Operating Cash Flow | $-94,689,000 |
| Cash Flow From Continuing Operating Activities | $-94,689,000 |
| Investing Activities | |
| Capital Expenditure | $-196,000 |
| Investing Cash Flow | $-247,006,000 |
| Cash Flow From Continuing Investing Activities | $-247,006,000 |
| Net Other Investing Changes | $-31,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $189,111,000 |
| Financing Cash Flow | $360,768,000 |
| Cash Flow From Continuing Financing Activities | $360,768,000 |
| Net Other Financing Charges | $171,273,000 |
| Net Common Stock Issuance | $189,111,000 |
| Common Stock Issuance | $189,111,000 |
| Other | |
| Issuance Of Debt | $0 |
| End Cash Position | $88,438,000 |
| Beginning Cash Position | $69,386,000 |
| Effect Of Exchange Rate Changes | $-21,000 |
| Changes In Cash | $19,073,000 |
| Proceeds From Stock Option Exercised | $384,000 |
| Net Issuance Payments Of Debt | $0 |
| Net Long Term Debt Issuance | $0 |
| Long Term Debt Issuance | $0 |
| Net Investment Purchase And Sale | $-246,779,000 |
| Sale Of Investment | $14,415,000 |
| Purchase Of Investment | $-261,194,000 |
| Net PPE Purchase And Sale | $-196,000 |
| Purchase Of PPE | $-196,000 |
| Change In Working Capital | $-8,197,000 |
| Change In Other Current Liabilities | $40,000 |
| Change In Other Current Assets | $-38,000 |
| Change In Payables And Accrued Expense | $3,770,000 |
| Change In Accrued Expense | $3,409,000 |
| Change In Payable | $361,000 |
| Change In Account Payable | $361,000 |
| Change In Prepaid Assets | $-11,969,000 |
| Other Non Cash Items | $21,667,000 |
| Stock Based Compensation | $20,009,000 |
| Amortization Of Securities | $-784,000 |
| Depreciation Amortization Depletion | $26,000 |
| Depreciation And Amortization | $26,000 |
| Depreciation | $26,000 |
| Net Income From Continuing Operations | $-127,410,000 |
Fetched: 2026-08-24